Bone Mineral Densitometry (BMD) Market

Bone Mineral Densitometry (BMD) Market Outlook (2024 to 2034)

The global bone mineral densitometry (BMD) market is estimated at a value of US$ 351.2 million in 2024 and is projected to expand at a CAGR of 3.5% to reach US$ 495.1 million by the end of 2034.

In recent times, the prevalence of osteoporosis and other bone-related diseases has risen, increasing the global demand for bone mineral densitometry. This technology is used to measure the mineral content in bones, specifically calcium and phosphorus, known as bone mineral density (BMD). Denser bones, rich in minerals, are stronger and less likely to fracture. Healthcare professionals use BMD assessments to diagnose osteoporosis, monitor the effectiveness of treatments, and predict fracture risks.

• The Centers for Disease Control and Prevention (CDC) reported that as of June 2023, over 54 million Americans, or more than 1 in 4 individuals, had arthritis, making it a significant health concern in the U.S.
• A study from UConn in June 2024 indicated that 10 million Americans aged 50 and above were estimated to have osteoporosis, with 2 million being men and the majority being women. Osteoporosis is characterized by substantial bone mass loss and reduced bone strength, increasing fracture risk.

The rising number of osteoporosis-related fractures and the disease's prevalence have driven the product demand. Consequently, more of these devices are being installed in healthcare facilities such as diagnostic centers, orthopedic clinics, and hospitals. Manufacturers are focusing on advancing volumetric scanning technology, which will enhance bone health management, predict future fracture risks, and implement preventive measures, thereby contributing to overall bone mineral densitometry market growth.

• According to the International Osteoporosis Foundation, global hip fracture rates for men and women are projected to increase by 310% and 240%, respectively, by 2050 compared to 1990 levels. This rise in osteoporosis and related fractures worldwide is projected to heighten demand for bone testing and densitometer installations.

This forecast by the International Osteoporosis Foundation is raising awareness about bone health.

Report Attribute	Detail
Bone Mineral Densitometry Market Size (2024E)	US$ 351.2 Million
Forecasted Market Value (2034F)	US$ 495.1 Million
Global Market Growth Rate (2024 to 2034)	3.5% CAGR
Canada Market Growth Rate (2024 to 2034)	3.3% CAGR
China Market Value (2034F)	US$ 47 Million
North America Market Share (2024E)	37.4%
East Asia Market Share (2034F)	22.5%
Key Companies Profiled	GE Healthcare Hologic Inc.; DMS Imaging; Swissray International Inc.; Xingaoyi Medical Equipment Co. Ltd.; Eurotec Medical Systems; Trivitron Healthcare AB; Medonica Co. Ltd.; Diagnostic Medical Systems Group.

What are the Opportunities Ahead for BMD Companies?

“Need for Improved Clinical Decision-Making and Emphasis on Enhancing Diagnostic Accuracy”

Reduced errors, high-resolution radiological images, and precise body composition assessments all enhance clinical decision-making. These tools provide physicians with essential guidelines and a range of calibration parameters. Additionally, the implementation of 3D modeling and visualization paves the way for innovative diagnostic methods, offering significant growth opportunities for businesses in this sector. Technological advancements are contributing to the expansion of the bone mineral densitometry market size.

As manufacturers are motivated to set specifications and requirements for the development of scanning facilities to evaluate various bone health management applications, the market will see further potential.

Another crucial factor is that women's bone density decreases by 30% to 50% as they age. The drop in estrogen levels after menopause significantly accelerates bone loss, making postmenopausal women highly susceptible to osteoporosis. Osteoporosis treatment is often recommended for over half of postmenopausal women and one-sixth of men aged 50 or older. This creates an opportunity for bone mineral densitometry manufacturers.

• According to Frontiers, demand for bone transplants has increased in recent decades due to various ailments and an aging population. Bone tissue engineering (BTE) uses a three-dimensional (3D) scaffold to create an environment conducive to cell proliferation and the regeneration of damaged tissues or organs.

What are the Challenges Encountered by Market Players?

“High Cost of BMD and Challenges in Transitioning to Digital Technology”

Dual-energy X-ray absorptiometry (DEXA) is a widely utilized method for measuring bone mineral density. However, its adoption in underdeveloped nations is hindered primarily by its high cost. These systems typically range from USD 9,180 to USD 199,000, making them unaffordable for many small and medium-sized hospitals with limited resources. Instead, these facilities often opt for less expensive conventional systems, posing a significant barrier to widespread adoption and hindering the transition from analog to digital systems.

Furthermore, healthcare institutions that do invest in these costly systems often rely on third-party payers (such as Medicare, Medicaid, or commercial health insurance plans) to offset expenses related to diagnostics, screenings, and treatments. However, the increasing cost of equipment coupled with declining reimbursements for bone density tests and diagnostic imaging scans further discourages medium-sized and smaller healthcare providers from investing in advanced technology.

Rising healthcare expenditures in developing countries are expected to make treatment procedures more affordable, potentially influencing future adoption rates of advanced diagnostic technologies.

Country-wise Evaluation

Japan is forecast to hold 35.1% of the East Asia bone mineral densitometry market share by the end of 2034.

What are the Opportunities for Bone Mineral Densitometer Producers in the United States?

“Rising Cases of Osteoporosis Fractures and Increased Hospitalizations for Orthopedic Issues”

Attribute	United States
Market Value (2024E)	US$ 113 Million
Growth Rate (2024 to 2034)	3.5% CAGR
Projected Value (2034F)	US$ 158 Million

Prevalence of osteoporosis and subsequent fractures in the population is driving one of the key bone mineral densitometry market trends in the United States.

• According to a 2020 article from the National Cancer Institute, osteoporotic fractures contribute to approximately 1.5 million cases annually in the United States alone, underscoring the expanding BMD market in the country.
• As reported by the Osteoporosis Foundation, globally, 1 in 3 women over 50 and 1 in 5 men over 50 may experience osteoporotic fractures. Moreover, individuals over 55 suffer up to 37 million fragility fractures annually, equating to about 70 fractures per minute.

Why are Market Players Directing Their Attention toward China?

“Several Government Initiatives to Improve Healthcare Accessibility and Quality”

Attribute	China
Market Value (2024E)	US$ 32 Million
Growth Rate (2024 to 2034)	4.2% CAGR
Projected Value (2034F)	US$ 47 Million

The government in China has made substantial investments in healthcare infrastructure and is actively promoting the adoption of advanced medical technologies. Policies and incentives designed to enhance healthcare services are fostering the use of sophisticated diagnostic equipment.

• A recent multicenter survey by the National Institute of Health reported an age-standardized prevalence of osteoporosis in China of 6.46% for men and 29.13% for women aged 50 and older. The survey also found varied bone mineral density (BMD) values influenced by demographic factors.
• According to the Medical Journal Hong Kong, osteoporosis is prevalent in the local community, affecting one in four postmenopausal women. Individuals with risk factors such as low body mass index, advanced age, prolonged menopause, and a family history of hip fracture or osteoporosis are advised to undergo DXA scans.

Category-wise Evaluation

Among the available technologies, such as DXA and Pdxa, DXA is favored by many due to its effectiveness and efficiency in delivering results. Competitors are focusing their efforts on this technology to capture a substantial share of the market.

Which Product Type is Widely Preferred by Patients in Hospitals?

“Preference for Axial Densitometers Due to Their Precise Measurements for Managing Bone Health”

Attribute	Axial
Segment Value (2024E)	US$ 243.6 Million
Growth Rate (2024 to 2034)	3.6% CAGR
Projected Value (2034F)	US$ 347.8 Million

Measuring bone mineral density in dense tissues like the pelvis, rib cage, and spine is challenging due to their composition. Axial bone densitometers provide accurate measurements in these critical areas. The prevalence of fractures and osteoporosis in the hips and spine underscores the necessity for axial bone densitometry.

Why is DXA Extensively Used in Assessing Bone Disorders?

“Role of DXA in Assessing Bone Health in Critical Areas Such as Hip and Spine”

Attribute	DXA
Segment Value (2024E)	US$ 225.9 Million
Growth Rate (2024 to 2034)	3.6% CAGR
Projected Value (2034F)	US$ 321.6 Million

The National Osteoporosis Foundation advocates for DXA testing, specifically for the hip and spine. The World Health Organization considers dual-energy X-ray absorptiometry (DXA) crucial for diagnosing osteoporosis through bone mineral density (BMD) assessments. Its extensive use in healthcare settings underscores its promotion by reputable organizations.

Competitive Landscape

Key players in the bone mineral densitometry industry are focusing on expanding their product lines and expanding into emerging countries. Several manufacturers are investing in the development of integrated software to understand bone geometry, perform volumetric analysis of cortical bone thickness, compute bone mineral density, and adapt themselves to evolving market trends such as bone biopsy and bone marrow processing.

• SOPHiA Genetics, a cloud-native software provider for the healthcare industry, announced in February 2023 that Synergy Laboratories, an Alabama full-service diagnostic laboratory, will now utilize SOPHiA DDM to provide sophisticated cancer profiling solutions. Synergy Laboratories intends to use this cutting-edge platform for cancer research and clinical trials to broaden the scope of its offerings.
• The United States Food and Drug Administration (FDA) announced in December 2022 that Mirati Therapeutics, a commercial-stage biotechnology firm, received a Breakthrough Therapy Designation (BTD) for adagrasib with cetuximab. This shows a potential therapeutic action for individuals with advanced colorectal cancer that has a mutation in the KRAS gene.

Fact.MR provides detailed information about the price points of key players in the bone mineral densitometry market positioned across the world, sales growth, production capacity, and speculative technological expansion, in this updated market report.

Key Segments of BMD Market Research

• By Product :

  • Axial Bone Densitometers
  • Peripheral Bone Densitometers

• By Technology :

  • Dual-Energy X-ray Absorptiometry
  • Peripheral Dual-Energy X-Ray Absorptiometry
  • Quantitative Ultrasound
  • Others

• By End User :

  • Hospitals
  • Orthopedic Clinics
  • Diagnostic Centers

• By Region :

  • North America
  • Latin America
  • Eastern Europe
  • Western Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa